NRx Pharmaceuticals, Inc. (NRXP) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-03-23
What protects it: the moat
It defends its pipeline using Breakthrough Therapy Designations, composition patents for NRX-101, and a citizen petition aimed at disqualifying preserved ketamine competitors.
Management asserts its preservative-free ketamine will command market share because the common preservative benzethonium chloride is toxic to corneal cells and potentially unsafe for repeated intravenous use. The company also holds multiple composition of matter patents for NRX-101 intended to ensure a substantial period of market exclusivity upon potential approval.
What growth costs
It allocated $3.8 million to research and development in 2025 while spending $13.1 million on administrative infrastructure to scale clinical operations.
Reinvestment is focused on completing NDA filings for NRX-100 and NRX-101 and expanding the HOPE clinic footprint beyond its initial locations in Florida. The business structurally requires funding for manufacturing technology transfers to U.S.-based partners and for conducting phase 2b/3 trials for new indications like augmenting Transcranial Magnetic Stimulation.
What could damage it
A $19.7 million working capital deficit and $306.9 million accumulated deficit create substantial doubt about its ability to continue as a going concern.
The company depends on raising additional capital during 2026 to fund its clinical programs and clinic acquisitions; failure to secure this financing would force a scale-back or elimination of research activities and prevent the planned commercial launch of KETAFREE in Q3 2026.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.